30 Nov 2012
Corporate author: PATH Malaria Vaccine Initiative

The PATH Malaria Vaccine Initiative’s (MVI) research and development strategy represents a multi-pronged approach to developing a next-generation malaria vaccine that would support efforts to move beyond reducing malaria disease and death to the longer-term goals of elimination and eradication. Malaria caused by Plasmodium falciparum, the deadliest of the malaria parasites affecting people, is the principal target of MVI’s efforts, due to the heavy toll of falciparum malaria in sub-Saharan Africa, where the bulk of malaria deaths occur.